Screener
Dianthus Therapeutics DNTH Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $5,274 | $9,725 |
| Accrued expenses | 31,125 | 19,452 |
| Current portion of deferred revenue | 1,485 | 1,188 |
| Current portion of operating lease liabilities | 399 | 367 |
| Total current liabilities | 38,283 | 30,732 |
| Deferred revenue | 6,322 | 5,770 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's accrued expenses?
- Dianthus Therapeutics (DNTH) reported accrued expenses of $31.13M in Q1 2026.
- How has Dianthus Therapeutics's accrued expenses changed year-over-year?
- Dianthus Therapeutics's accrued expenses increased by 290.1% year-over-year, from $7.98M to $31.13M.
- What is the long-term trend for Dianthus Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's accrued expenses has grown at a 20.5% compound annual growth rate (CAGR), from $7.67M to $19.45M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Dianthus Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude